Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2003, p. 3116-3125, Vol. 23, No. 9
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.9.3116-3125.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213
Received 31 October 2002/ Returned for modification 11 December 2002/ Accepted 6 February 2003
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Tor1 and Tor2 are highly similar in their amino acid sequences. Mutations in either Tor1 or Tor2 that prevent it from binding to the rapamycin-immunophilin complex confer on yeast cells rapamycin resistance in a dominant manner (7, 32, 48), indicating that the two proteins are redundant in functions sensitive to rapamycin. However, Tor2 has a unique function that cannot be performed by Tor1. This unique function of Tor2 requires its kinase activity but is not sensitive to rapamycin inhibition (53). Genetic studies have suggested that the unique Tor2 function is required for organization of the actin cytoskeleton during the cell cycle (44). TOR2 mutants that display random distribution of actin during the cell cycle have been isolated (18). This type of defects is not observed in cells depleted for TOR1, nor can it be suppressed by TOR1 (18). Tor2 appears to control the actin cytoskeleton via a Rho GTPase-dependent mechanism. Overexpression of RHO1 and RHO2, two genes encoding Rho GTPases, is able to suppress the actin defects in tor2 mutants (42). In addition, it has been found that the activity of Rom2, a guanine nucleotide exchange factor of Rho GTPases, is significantly reduced in a tor2 mutant displaying actin cytoskeleton defects, indicating that Tor2 regulates Rho GTPases via Rom2 (42, 43). However, the mechanism by which Tor2 controls Rom2 remains elusive.
Type 2A protein phosphatases (PP2A) and 2A-like protein phosphatases have recently emerged as major downstream effectors of the Tor proteins (4, 10, 22, 36). In yeast, two closely related genes, PPH21 and PPH22, encode two functionally redundant catalytic subunits of PP2A (PP2Ac) (47), which exist primarily in cells as a heterotrimeric complex with two regulatory subunits, designated A and B. The product of the TPD3 gene serves as the A subunit, and two distinct proteins, encoded by CDC55 and RTS1, serve as alternative B subunits (16, 45, 52). Deletion of both PPH21 and PPH22 eliminates most of the cellular PP2A activity and drastically reduces cell growth (47). Deletion of a third gene, PPH3, in combination with a pph21 pph22 double deletion, is lethal (39). The PPH3 gene encodes a 2A-like phosphatase that differs from PP2A in its enzymatic properties and subunit composition (20). Yeast cells contain a second 2A-like phosphatase catalytic subunit, encoded by SIT4, which performs cellular functions distinct from those of Pph21 and Pph22 (49). Sit4 normally associates with a family of related proteins, termed Sap proteins, including Sap155, Sap185, Sap190, and possibly Sap4 (33). Sit4 complexed with any of the Sap proteins promotes progression through G1 via regulation of G1 cyclin production (12, 49).
The Tor proteins regulate PP2A and 2A-like phosphatases in yeast via an essential protein encoded by the TAP42 gene, which was isolated via its genetic interaction with SIT4 and PPH21 (10). When overexpressed, TAP42 suppresses the Ts- phenotype produced by sit4-102 and pph21-102, two mutant alleles that have been used extensively for studying the function of the Sit4 and Pph21 phosphatases (10, 12, 31, 49). Tap42 forms complexes with either PP2Ac, Pph21 and Pph22, or 2A-like phosphatase Sit4. These Tap42-containing complexes are structurally independent of the conventional holoenzyme of the phosphatases (10, 22). Tap42 is a phosphoprotein whose phosphorylation depends on the Tor proteins (22). The Tor-dependent phosphorylation of Tap42 appears to promote its interaction with phosphatases, since inactivation of the Tor proteins by rapamycin treatment or nutrient depletion prevents formation of the Tap42-phosphatase complexes (10).
The Tap42-phosphatase complexes appear to play a key role in the Tor pathway. Mutations in TAP42 have been shown to confer on yeast cells rapamycin resistance. In addition, Tap42 has been found to be associated with PP2Ac and Sit4 only in actively growing cells, not in cells entering stationary phase, indicating that formation of the Tap42-phosphatase complexes is essential for cell growth (10). Despite these findings, the precise role of these complexes in the Tor pathway and the effect of the Tap42 interaction on the activity of the phosphatases are not clear. Nevertheless, the observed straight correlation between the dissociation of phosphatases from Tap42 and their activation suggests that Tap42 may act as a phosphatase inhibitor (2, 5, 21).
Previous studies have revealed roles for the Tap42-Sit4 complex in Tor-mediated gene expression. Several transcription factors for genes involved in nutrient metabolism have been identified as the targets of this complex (2). However, the role of the Tap42-PP2Ac complex in the Tor pathway is largely unknown. To better understand this complex, we sought to identify PP2Ac mutants that are defective in its formation. We found that the mutant Pph21 phosphatase encoded by pph21-102, a well-characterized phosphatase mutant allele (31), was specifically defective in its interaction with Tap42. This finding, together with the fact that cells carrying this mutant gene were defective in actin cytoskeleton organization (31), raised the possibility that the Tap42-Pph21 complex was involved in controlling the polarized distribution of actin during the cell cycle. We confirmed this notion by demonstrating that mutations in Tap42 that perturb its interaction with Pph21 cause the same defects. Our results suggest that it is the Tap42-PP2Ac complex rather than the PP2A holoenzyme that is involved in the organization of the actin cytoskeleton. In addition, we provide evidence that PP2A activity negatively regulates the actin cytoskeleton via a Rho GTPase-dependent mechanism.
| MATERIALS AND METHODS |
|---|
|
|
|---|
|
|
Construction of plasmid RHO2-pRS424 (pJY714). A 1.4-kb DNA fragment containing the RHO2 open reading frame was amplified from yeast genomic DNA by PCR using high-fidelity Taq DNA polymerase (Roche). The PCR products were digested with SacI and XhoI, whose sites were introduced via the 5' and 3' primers, respectively, and cloned into pRS424 (46) at the corresponding sites. The 5' primer for the PCR was 5'-ATACATGAGCTCCAACTGCTACACCATTTA -3'. The 3' primer was 5'-ATACATCTCGAGCTATGGTTTGATGTGCCA-3'. The underlined regions are where the restriction sites lie.
Preparation of cell extracts. Yeast cells were grown in appropriate medium to early log phase. Cells were collected, washed twice with ice-cold lysis buffer (50 mM Tris-Cl [pH 7.4], 50 mM NaF, 5 mM EDTA, 1 mM dithiothreitol [DTT], 5% glycerol), resuspended in the same buffer containing 1x protease inhibitor cocktails (Roche), and lysed by vortexing with glass beads. Cell lysates were diluted fourfold with wash buffer containing 50 mM Tris-Cl (pH 7.4), 50 mM NaF, 200 mM NaCl, 1 mM DTT, 1% Triton X-100, and 1x protease inhibitors. Insoluble cell debris was removed by centrifugation at 12,000 x g for 15 min, and the supernatants were then used for coimmunoprecipitation (see below). Protein concentration in the supernatants was determined by using the Bio-Rad protein assay.
Cross-linking anti-Tap42 antibody to protein A-Sepharose beads. An aliquot of anti-Tap42 serum (1 ml) was diluted 10-fold with phosphate-buffered saline (PBS) and incubated with 1 ml of protein A-conjugated Sepharose beads (Zymed) at 4°C for 2 h with gentle shaking. The beads were washed three times with PBS buffer and twice with 0.2 M sodium borate (pH 9.0). After the final wash, the beads were resuspended in 10 ml of the sodium borate buffer. The cross-linking reaction was carried out by using dimethylpimelimidate (Pierce) as described before (15).
Coimmunoprecipitation. To precipitate Tap42, an aliquot of cell extract containing 1 mg of protein was incubated with 20 µl of protein A beads conjugated with the anti-Tap42 antibody at 4°C for 3 h. After the incubation, beads were washed three times with wash buffer (50 mM Tris-Cl [pH 7.4], 200 mM NaCl, 1 mM DTT, 1% Triton X-100) and once with 20 mM Tris-Cl, pH 7.4, and boiled for 5 min in 70 µl of 2x sodium dodecyl sulfate (SDS) sample buffer. An aliquot (20 µl) of sample was fractionated with an SDS-10% polyacrylamide gel and transferred to a nitrocellulose membrane, which was then immunoblotted with anti-Tap42 (1:1,000 dilution), anti-Sit4 (1:1,000 dilution), or anti-HA epitope (12CA5 at 1:1,000 dilution) antibodies. To precipitate Tpd3, an aliquot of extract containing 1 mg of protein was incubated with 2 µl of anti-Tpd3 antibody at 4°C for 2 h. The Tpd3 protein-antibody complexes were then precipitated with protein A beads during a 90-min incubation at 4°C. Beads were washed three times with wash buffer and once with 20 mM Tris-Cl, pH 7.4, and boiled for 5 min in 70 µl of 2x SDS sample buffer. Western blot analysis was then performed as described above with anti-Tpd3 (1:2,000) and anti-HA epitope (12CA5; 1:1,000 dilution) antibodies.
Protein phosphatase assays.
Cell extracts for the phosphatase assays were made as described before (34). 32P-labeled calf thymus H1 histone (Sigma) was prepared by phosphorylation with the catalytic subunit of cyclic AMP-dependent protein kinase (PKA) (Sigma) in reaction buffer containing 50 mM Tris-Cl (pH 7.4), 10 mM MgCl2, 10 mM 2-mercaptoethanol, 100 µM ATP, and [
-32P]ATP (10 mCi/mmol). After incubation at 30°C for 4 h, the reaction was terminated by the addition of PKA inhibitor (100 nM; Sigma). Unincorporated labeled nucleotides were removed from the reaction mixture with a Micro Bio-spin column (Bio-Rad) by following the manufacturer's instructions. The H1 histone phosphatase activity in the cell extracts was determined as described before (9). Bacterially expressed type 1 phosphatase inhibitor 2 (I-2; New England Laboratory) was used at a concentration of 10 nM.
Fluorescence microscopy. Yeast cells were grown to early log phase at 23°C and shifted to 37°C for 4 h. The cells were fixed directly in growth medium with 3.7% formaldehyde at room temperature for 30 min. The cells were then collected and resuspended in PBS containing 3.7% formaldehyde. After incubation at room temperature for 1 h, the cells were washed three times with PBS and stained with Alexa-conjugated phalloidin (Molecular Probes) as described before (38). Stained cells were visualized with a Zeiss Axiovert microscope by either differential interference contrast (DIC) or fluorescence microscopy.
| RESULTS |
|---|
|
|
|---|
|
Tap42 is required for the cell cycle-dependent polarized distribution of actin.
Previous studies have demonstrated that the pph21-102 cells are defective in the polarized distribution of actin during the cell cycle (31). Our finding that the mutant cells are defective for formation of the Tap42-Pph21 complex raised the possibility that the Tap42-Pph21 complex was required for organization of the actin cytoskeleton during the cell cycle. To test this notion, we examined the assembly of the actin cytoskeleton in tap42 Ts- allele tap42-11, which was isolated previously (10). Exponentially growing tap42-11 cells were shifted from 23 to 37°C for 4 h. Cells before and after the shift were fixed, stained with fluorescent phalloidin, and imaged. As shown in Fig. 2, when grown at 23°C, the tap42-11 cells had an increased size and round cell morphology in comparison with wild-type cells (Fig. 2A and B, DIC) (10). Despite this, these mutant cells displayed a normal distribution of actin in all phases of the cell cycle (Fig. 2B). In 73% of the unbudded cells actin patches were found to form the actin cap at the site of the future bud. In 91% of the cells containing small and midsize buds actin patches accumulated in the daughter cells and, in most cases, actin cables that ran in parallel to the longitudinal axis of the cell were clearly visible. In 57% of the large-budded cells actin patches were concentrated at the mother-bud neck (Table 3). Following the incubation at 37°C, however, actin cables vanished and the normal asymmetric distribution of the actin patches during the cell cycle was replaced with a randomized distribution pattern (Fig. 2C). The percentages of cells displaying a polarized distribution of actin in the stages of unbudded, small- and midsize-budded, and large-budded cells fell to 13, 22, and 2%, respectively (Table 3). These observations suggest that Tap42 is required for the cell cycle-dependent polarized distribution of actin. It is noteworthy that after a 4-h incubation at the nonpermissive temperature, a significant portion (
50%) of the tap42-11 cells arrested as unbudded cells, indicating a late G1 arrest, while many others (31%) arrested as large-budded cells, a characteristic of a G2/M arrest.
|
|
|
The pph21 pph22 double-deletion cells display a normal actin cytoskeleton. Studies on the Tap42-phosphatase complexes have revealed a correlation between dissociation of a phosphatase from Tap42 and its activation (2, 5, 21). Since the Pph21 phosphatase disassociates from Tap42 when the pph21-102 cells are incubated at the nonpermissive temperature (Fig. 1), it is possible that the actin defects associated with the mutant cells are caused by an unregulated Pph21 phosphatase rather than by the inactivation of Pph21. To test this notion, we examined the actin cytoskeleton in cells depleted of both PPH21 and PPH22 (pph21 pph22). We reasoned that if the actin defects in the pph21-102 cells were caused by inactivation of the phosphatase, we would expect to observe the same defects in cells depleted of both Pph21 and Pph22. However, this was not the case. The pph21 pph22 double-deletion cells grew slowly at 23°C and ceased to grow at 37°C; thus, they were temperature sensitive. Nevertheless, we failed to detect any significant defects in organization of the actin cytoskeleton at all phases of the cell cycle under both conditions (Fig. 4 and Table 3). It is worth noting that the pph21-102 allele used in this study has a pph22 background (pph21-102 pph22); therefore, the PP2A activity in the pph21-102 pph22 cells can hardly be lower than that in the pph21 phh22 double-deletion strain, indicating that the actin defects in the pph21-102 cells are not caused by the absence of PP2A activity.
|
|
|
|
The organization of the actin cytoskeleton is sensitive to rapamycin. Previous studies have demonstrated that the interaction between Tap42 and phosphatases is regulated by the Tor proteins and is sensitive to rapamycin (10). The finding that the Tap42-PP2Ac complex is required for organization of the actin cytoskeleton suggests that this particular cellular event ought to be rapamycin sensitive. To test this notion, we examined the distribution of actin in wild-type cells treated with rapamycin. We found that the drug-treated cells displayed a random distribution of actin in all phases of the cell cycle. The actin cables normally observed in untreated cells were completely absent (Fig. 8A). Nevertheless, rapamycin failed to perturb the normal distribution of actin in cells expressing TOR1S1972R, a rapamycin-resistant TOR1 gene (Fig. 8B). These observations indicate that organization of the actin cytoskeleton in yeast is sensitive to rapamycin and that a functional TOR1 alone is able to sustain a normal actin cytoskeleton.
|
| DISCUSSION |
|---|
|
|
|---|
Recent studies of the Tap42-phosphatase complexes have revealed a straight correlation between the dissociation of the phosphatases from Tap42 and their activation (2, 5, 21). This observation has led to the suggestion that Tap42 downregulates the activity of the phosphatases with which it associates. In this regard, the dissociation of PP2Ac from Tap42 that occurs when the pph21-102 and tap42-11 cells are grown at the nonpermissive temperature is expected to result in an activation of the phosphatase. It is thus likely that the actin defects associated with the mutant cells are caused by an upregulated PP2A activity rather than by a loss of PP2A activity. This conclusion is in accordance with the finding that both tap42-11 and pph21-102 cells display a normal PP2A activity at the nonpermissive temperature (Fig. 5) and is further supported by the observation that inactivation of both Pph21 and Pph22 does not cause any defects in the organization of the actin cytoskeleton (Fig. 4). Therefore, our results suggest a negative role for PP2A activity in the organization of the actin cytoskeleton during the cell cycle, in contrast to the positive role suggested by the previous studies (31).
Tap42-PP2Ac controls the actin cytoskeleton via a Rho GTPase-dependent mechanism. Formation of the Tap42-PP2Ac complex occurs in actively growing cells, in which the Tor proteins are active, but not in cells treated with rapamycin (10), suggesting that Tap42 associates with PP2Ac in a Tor-dependent and rapamycin-sensitive manner. Therefore, the finding that the organization of the actin cytoskeleton requires the Tap42-PP2Ac complex indicates that this process is downstream of the Tor proteins and ought to be rapamycin sensitive. Indeed, we found that cells treated with rapamycin exhibited a perturbed actin cytoskeleton (Fig. 8). However, in this case, we cannot rule out the possibility that the effect of rapamycin is due to inhibition of the Tor-dependent protein synthesis (1). Since Tap42 has been shown to be required for protein synthesis (10), is it possible that the defects in the actin cytoskeleton associated with tap42-11 and pph21-102 are caused indirectly by a reduction in protein synthesis? Several lines of evidence argue against this possibility. First, a study on the pph21-102 allele has demonstrated that the mutant cells maintain a level of protein synthesis similar to that of wild-type cells a few hours after being shifted to the nonpermissive temperature and continue to increase in size despite an arrest at G2/M (31). Second, unlike rapamycin-treated cells, which arrest at early G1 phase as small unbudded cells as a consequence of a reduction in protein synthesis (1), the tap42-11 cells arrest either as large unbudded or large-budded cells after a 4-h incubation at the nonpermissive temperature, during which the size of the cells keeps increasing (Fig. 2, DIC, compare panels B and C) (10). The large unbudded morphology is a characteristic of cells undergoing a late G1 arrest and is likely to be a consequence of the defect in formation of the Tap42-Sit4 complex in the mutant cells rather than a consequence of reduction in protein synthesis (Fig. 2B). Finally, the actin defects in both the tap42-11 and pph21-102 cells are suppressed by overexpression of RHO2 (Fig. 7), suggesting that the Tap42-Pph21 complex controls the actin cytoskeleton via a Rho GTPase-dependent mechanism.
Intriguingly, it is thought that regulation of the actin cytoskeleton is Tor2 specific and that Tor1 does not have a role; defects in the actin cytoskeleton have been found to be associated only with mutations in TOR2 and are not suppressed by the presence of TOR1 (18). On the other hand, our finding that the cell cycle-dependent distribution of actin requires the Tap42-PP2Ac complex, which in turn requires the shared function of the Tor proteins (10), suggests that this process is regulated redundantly by Tor1 and Tor2. Therefore, it is possible that regulation of the actin cytoskeleton is not the unique Tor2 function. In accordance with this view, it has been found that the mutant Tor2 proteins that are defective in actin cytoskeleton organization are unable to provide the shared function, implying that they are also defective in the shared function (18). In addition, given the fact that the Tor proteins regulate phosphorylation levels of many cellular proteins via the Tap42-phosphatase complexes (2, 5, 21), it is possible that Tor signaling activity controls the phosphorylation of a factor(s) involved in modulating Rho GTPases. In this view, the finding that Rom2 exhibits a Tor2-dependent activity toward Rho GTPases suggests that this protein may be the target of the Tap42-PP2Ac complex (42).
Rho1 and Rho2 GTPases control the actin cytoskeleton via the Pkc1-mitogen-activated protein kinase (MAPK) pathway in yeast (43). Since overexpression of RHO2 suppresses the actin defects associated with the pph21, tap42, and tor2 mutants, it is expected that the Pkc1-MAPK pathway is downregulated in these mutants (Fig. 7) (6, 19). However, it has been recently found that inactivation of the Tor proteins by rapamycin induces hyperactivation of the Pkc1-MAPK pathway and consequently actin depolarization (51). Furthermore, the rapamycin-induced actin depolarization requires Sit4 and Tap42, since inactivation of Sit4 or mutations in TAP42 nullify the effect of the drug (51). It thus appears that the Tor proteins negatively regulate the Pkc1-MAPK pathway via the Tap42-Sit4 complex, a notion that is inconsistent with our findings. One way to explain this paradox is to suggest that the Tor proteins are able to control the Pkc1-MAPK pathway via two different mechanisms. In support of this, it has been shown that rapamycin has its effect at the cell surface, presumably by altering cell wall integrity (25, 51), whereas the downregulation of the Pkc1-MAPK1 pathway in the tor2 mutants was found to be independent of the cell surface alterations (6). Since rapamycin-induced hyperactivation of the Pkc1-MAPK pathway can be suppressed under osmotically stable conditions, it is likely that the hyperactivation of the Pkc1-MAPK pathway in the cells treated with rapamycin is caused by the cell wall remodeling during the transition into the quiescent phase (25, 51). In accordance with this notion, it has been found that the hyperactivation of the Pkc1-MAPK pathway induced by rapamycin is transient (25). Constitutive activation of the Pkc1-MAPK pathway, as happens in the sit4 deletion cells and in the tap42-11 cells grown at the permissive temperature, not only fails to perturb the actin cytoskeleton but also prevents rapamycin from doing so (51). It is thus appears that rapamycin-induced actin depolarization is caused by a transient activation of the Pkc1-MAPK pathway as a consequence of changes in cell wall integrity.
The role of the Tap42-PP2Ac complex in the G2/M transition.
In addition to the defects in the organization of the actin cytoskeleton, the pph21-102 cells are also defective in the G2/M transition, which is characterized by a G2/M block at the nonpermissive temperature. Since the pph21-102 cells are impaired in the function of the Tap42-PP2Ac complex rather than in that of the PP2A holoenzyme (Fig. 1), the G2/M block associated with the mutant cells suggests a role for the Tap42-PP2Ac complex in controlling the G2/M transition. This notion is supported by the fact that overexpression of TAP42 is able to suppress the Ts- phenotype, and by inference the G2/M block, caused by the pph21-102 allele (10, 31). Although the terminal phenotype of the tap42-11 cells grown at the nonpermissive temperature is a predominant G1 arrest (
50% of cells arrests as large unbudded cells in our strain background), a significant portion (
31%) of the cells arrest with a large bud, a characteristic of a G2/M arrest (H. Wang, unpublished observation). The G1 arrest associated with the mutant cells is likely to be a consequence of the defects in the Tap42-Sit4 complex, which is required for the G1/S transition (Fig. 3) (H. Wang, submitted for publication). In accordance with this, we have recently found that when the tap42-11 cells treated with hydroxyurea, which were arrested at S phase, were released into hydroxyurea-free medium at the nonpermissive temperature, the majority (
67%) of the cells were arrested as large-budded cells. This observation suggests that, upon release from S phase, the mutant cells were unable to progress into G1 phase at the nonpermissive temperature (data not shown). Although it is possible that the G2/M block in the tap42-11 and pph21-102 cells is caused by activation of the morphogenesis checkpoint in response to the defects in the actin cytoskeleton (30), our finding that overexpression of RHO2 suppresses the actin defects but not the Ts- phenotype of the pph21-102 cells argues against it. Taking these results together, we suggest that the Tap42-PP2Ac complex is involved in controlling the G2/M transition of yeast cells. Since the Tap42-PP2Ac complex acts downstream of the Tor proteins, our finding further suggests a role for the Tor signaling pathway in controlling entry into mitosis in the yeast cell cycle.
It has been suggested that in yeast PP2A plays a positive role in entry into mitosis, a conclusion that is contradictory to the findings from other systems, in which PP2A has been shown to play a negative role in the same process (23, 28, 29, 31). Since the conclusion is largely based on the studies of the pph21-102 allele, our finding that this mutant is specifically defective in the formation of the Tap42-PP2Ac complex rather than the PP2A holoenzyme offers a different interpretation for the role of PP2A activity in the G2/M transition. For the same reasons that led us to suggest that PP2A activity negatively regulates the actin cytoskeleton, the involvement of the Tap42-PP2Ac complex in the G2/M transition prompts us to propose a negative role for PP2A activity in this process. Further study of the role of the Tap42-PP2Ac complex in the G2/M transition will allow us to test this notion. In addition, it is worth noting that, in Xenopus laevis, the PP2A activity that negatively regulates the G2/M transition has been found to be elicited by a novel form of PP2A, termed INH, rather than the PP2A holoenzyme (28).
The role of Tap42 in PP2A regulation.
Mutational analyses of the genes for PP2Ac have established the role of PP2Ac in three important cellular processes, namely, organization of the actin cytoskeleton, regulation of the G2/M transition, and control of cell wall integrity (11, 31). Since cell wall integrity is regulated by the Pkc1-MAPK pathway, in which Rho1 and Rho2 GTPases partake (43), the connection between the Tap42-PP2Ac complex and the Rho GTPases indicates a role for the complex in this process. As such, Tap42 is involved in all the processes in which PP2Ac has an established role. Since Tap42 has been found to be associated with only
5% of PP2Ac under normal conditions (10), the fact that the previous studies of PP2Ac reveal only the function of the Tap42-PP2Ac complex, not that of the PP2A holoenzyme, underscores the importance of Tap42 in PP2Ac regulation.
| ACKNOWLEDGMENTS |
|---|
This work was supported by the CMRF fund from University of Pittsburgh School of Medicine and by the Startup fund to Y.J.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Beck, T., and M. N. Hall. 1999. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature 402:689-692.[CrossRef][Medline]
3. Berset, C., H. Trachsel, and M. Altmann. 1998. The TOR (target of rapamycin) signal transduction pathway regulates the stability of translation initiation factor eIF4G in the yeast Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 95:4264-4269.
4. Bertram, P. G., J. H. Choi, J. Carvalho, W. Ai, C. Zeng, T. F. Chan, and X. F. Zheng. 2000. Tripartite regulation of Gln3p by TOR, Ure2p, and phosphatases. J. Biol. Chem. 275:35727-35733.
5. Bertram, P. G., C. Zeng, J. Thorson, A. S. Shaw, and X. F. Zheng. 1998. The 14-3-3 proteins positively regulate rapamycin-sensitive signaling. Curr. Biol. 8:1259-1267.[CrossRef][Medline]
6. Bickle, M., P. A. Delley, A. Schmidt, and M. N. Hall. 1998. Cell wall integrity modulates RHO1 activity via the exchange factor ROM2. EMBO J. 17:2235-2245.[CrossRef][Medline]
7. Cafferkey, R., P. R. Young, M. M. McLaughlin, D. J. Bergsma, Y. Koltin, G. M. Sathe, L. Faucette, W. K. Eng, R. K. Johnson, and G. P. Livi. 1993. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol. Cell. Biol. 13:6012-6023.
8. Cardenas, M. E., N. S. Cutler, M. C. Lorenz, C. J. Di Como, and J. Heitman. 1999. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 13:3271-3279.
9. Cohen, P., S. Alemany, B. A. Hemmings, T. J. Resink, P. Stralfors, and H. Y. Tung. 1988. Protein phosphatase-1 and protein phosphatase-2A from rabbit skeletal muscle. Methods Enzymol. 159:390-408.[Medline]
10. Di Como, C. J., and K. T. Arndt. 1996. Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Dev. 10:1904-1916.
11. Evans, D. R., and M. J. Stark. 1997. Mutations in the Saccharomyces cerevisiae type 2A protein phosphatase catalytic subunit reveal roles in cell wall integrity, actin cytoskeleton organization and mitosis. Genetics 145:227-241.[Abstract]
12. Fernandez-Sarabia, M. J., A. Sutton, T. Zhong, and K. T. Arndt. 1992. SIT4 protein phosphatase is required for the normal accumulation of SWI4, CLN1, CLN2, and HCS26 RNAs during late G1. Genes Dev. 6:2417-2428.
13. Guthrie, C., and G. R. Fink. 1991. Guide to yeast genetics and molecular biology. Academic Press, Inc., New York, N.Y.
14. Hardwick, J. S., F. G. Kuruvilla, J. K. Tong, A. F. Shamji, and S. L. Schreiber. 1999. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA 96:14866-14870.
15. Harlow, E. D., and D. Lane. 1988. Antibodies: a laboratory manual, p. 519-552. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
16. Healy, A. M., S. Zolnierowicz, A. E. Stapleton, M. Goebl, A. A. DePaoli-Roach, and J. R. Pringle. 1991. CDC55, a Saccharomyces cerevisiae gene involved in cellular morphogenesis: identification, characterization, and homology to the B subunit of mammalian type 2A protein phosphatase. Mol. Cell.Biol. 11:5767-5780.
17. Heitman, J., N. R. Movva, and M. N. Hall. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909.
18. Helliwell, S. B., I. Howald, N. Barbet, and M. N. Hall. 1998. TOR2 is part of two related signaling pathways coordinating cell growth in Saccharomyces cerevisiae. Genetics 148:99-112.
19. Helliwell, S. B., A. Schmidt, Y. Ohya, and M. N. Hall. 1998. The Rho1 effector Pkc1, but not Bni1, mediates signalling from Tor2 to the actin cytoskeleton. Curr. Biol. 8:1211-1214.[CrossRef][Medline]
20. Hoffmann, R., S. Jung, M. Ehrmann, and H. W. Hofer. 1994. The Saccharomyces cerevisiae gene PPH3 encodes a protein phosphatase with properties different from PPX, PP1 and PP2A. Yeast 10:567-578.[CrossRef][Medline]
21. Jacinto, E., B. Guo, K. T. Arndt, T. Schmelzle, and M. N. Hall. 2001. TIP41 interacts with TAP42 and negatively regulates the TOR signaling pathway. Mol. Cell 8:1017-1026.[CrossRef][Medline]
22. Jiang, Y., and J. R. Broach. 1999. Tor proteins and protein phosphatase 2A reciprocally regulate Tap42 in controlling cell growth in yeast. EMBO J. 18:2782-2792.[CrossRef][Medline]
23. Kinoshita, N., H. Ohkura, and M. Yanagida. 1990. Distinct, essential roles of type 1 and 2A protein phosphatases in the control of the fission yeast cell division cycle. Cell 63:405-415.[CrossRef][Medline]
24. Koltin, Y., L. Faucette, D. J. Bergsma, M. A. Levy, R. Cafferkey, P. L. Koser, R. K. Johnson, and G. P. Livi. 1991. Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol. Cell. Biol. 11:1718-1723.
25. Krause, S. A., and J. V. Gray. 2002. The protein kinase C pathway is required for viability in quiescence in Saccharomyces cerevisiae. Curr. Biol. 12:588-593.[CrossRef][Medline]
26. Kunkel, T. A., K. Bebenek, and J. McClary. 1991. Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol. 204:125-139.[Medline]
27. Kunz, J., R. Henriquez, U. Schneider, M. Deuter-Reinhard, N. R. Movva, and M. N. Hall. 1993. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73:585-596.[CrossRef][Medline]
28. Lee, T. H., M. J. Solomon, M. C. Mumby, and M. W. Kirschner. 1991. INH, a negative regulator of MPF, is a form of protein phosphatase 2A. Cell 64:415-423.[CrossRef][Medline]
29. Lee, T. H., C. Turck, and M. W. Kirschner. 1994. Inhibition of cdc2 activation by INH/PP2A. Mol. Biol. Cell 5:323-338.[Abstract]
30. Lew, D. J. 2000. Cell-cycle checkpoints that ensure coordination between nuclear and cytoplasmic events in Saccharomyces cerevisiae. Curr. Opin. Genet. Dev. 10:47-53.[CrossRef][Medline]
31. Lin, F. C., and K. T. Arndt. 1995. The role of Saccharomyces cerevisiae type 2A phosphatase in the actin cytoskeleton and in entry into mitosis. EMBO J. 14:2745-2759.[Medline]
32. Lorenz, M. C., and J. Heitman. 1995. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J. Biol. Chem. 270:27531-27537.
33. Luke, M. M., F. Della Seta, C. J. Di Como, H. Sugimoto, R. Kobayashi, and K. T. Arndt. 1996. The SAP, a new family of proteins, associate and function positively with the SIT4 phosphatase. Mol. Cell. Biol. 16:2744-2755.[Abstract]
34. Nickels, J. T., and J. R. Broach. 1996. A ceramide-activated protein phosphatase mediates ceramide-induced G1 arrest of Saccharomyces cerevisiae. Genes Dev. 10:382-394.
35. Noda, T., and Y. Ohsumi. 1998. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J. Biol. Chem. 273:3963-3966.
36. Peterson, R. T., B. N. Desai, J. S. Hardwick, and S. L. Schreiber. 1999. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin associated protein. Proc. Natl. Acad. Sci. USA 96:4438-4442.
37. Powers, T., and P. Walter. 1999. Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae. Mol. Biol. Cell 10:987-1000.
38. Pringle, J. R., A. E. M. Adams, D. G. Drubin, and B. K. Haarer. 1991. Immunofluorescence methods for yeast. Methods Enzymol. 194:565-602.[Medline]
39. Ronne, H., M. Carlberg, G. Z. Hu, and J. O. Nehlin. 1991. Protein phosphatase 2A in Saccharomyces cerevisiae: effects on cell growth and bud morphogenesis. Mol. Cell. Biol 11:4876-4884.
40. Rothstein, R. 1991. Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast. Methods Enzymol. 194:281-301.[CrossRef][Medline]
41. Schmelzle, T., and M. N. Hall. 2000. TOR, a central controller of cell growth. Cell 103:253-262.[CrossRef][Medline]
42. Schmidt, A., M. Bickle, T. Beck, and M. N. Hall. 1997. The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell 88:531-542.[CrossRef][Medline]
43. Schmidt, A., and M. N. Hall. 1998. Signaling to the actin cytoskeleton. Annu. Rev. Cell Dev. Biol. 14:305-338.[CrossRef][Medline]
44. Schmidt, A., J. Kunz, and M. N. Hall. 1996. TOR2 is required for organization of the actin cytoskeleton in yeast. Proc. Natl. Acad. Sci. USA 93:13780-13785.
45. Shu, Y., H. Yang, E. Hallberg, and R. Hallberg. 1997. Molecular genetic analysis of Rts1p, a B' regulatory subunit of Saccharomyces cerevisiae protein phosphatase 2A. Mol. Cell. Biol. 17:3242-3253.[Abstract]
46. Sikorski, R. S., and P. Hieter. 1989. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27.
47. Sneddon, A. A., P. T. Cohen, and M. J. Stark. 1990. Saccharomyces cerevisiae protein phosphatase 2A performs an essential cellular function and is encoded by two genes. EMBO J. 9:4339-4346.[Medline]
48. Stan, R., M. M. McLaughlin, R. Cafferkey, R. K. Johnson, M. Rosenberg, and G. P. Livi. 1994. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. J. Biol. Chem. 269:32027-32030.
49. Sutton, A., D. Immanuel, and K. T. Arndt. 1991. The SIT4 protein phosphatase functions in late G1 for progression into S phase. Mol. Cell. Biol. 11:2133-2148.
50. Thomas, B. J., and R. Rothstein. 1989. Elevated recombination rates in transcriptionally active DNA. Cell 56:619-630.[CrossRef][Medline]
51. Torres, J., C. J. Di Como, E. Herrero, and M. A. De La Torre-Ruiz. 2002. Regulation of the cell integrity pathway by rapamycin-sensitive TOR function in budding yeast. J. Biol. Chem. 277:43495-43504.
52. van Zyl, W., W. Huang, A. A. Sneddon, M. Stark, S. Camier, M. Werner, C. Marck, A. Sentenac, and J. R. Broach. 1992. Inactivation of the protein phosphatase 2A regulatory subunit A results in morphological and transcriptional defects in Saccharomyces cerevisiae. Mol. Cell. Biol. 12:4946-4959.
53. Zheng, X. F., D. Florentino, J. Chen, G. R. Crabtree, and S. L. Schreiber. 1995. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82:121-130.[CrossRef][Medline]
This article has been cited by other articles:
| ||||||||||||||||||||||||||||